Breast CancerPhase 1/2NCT00002873
Radiation Therapy in Treating Women With Stage I or Stage II Breast Cancer
A Phase 1/2 study testing brachytherapy in people with Breast Cancer, run by Radiation Therapy Oncology Group at 232 sites in 2 countries.
Trial summary
RATIONALE: Radiation therapy may kill any tumor cells remaining after surgery. PURPOSE: Phase I/II trial to study the effectiveness of brachytherapy in treating women who have stage I or stage II breast cancer. Read more about this study
- Who is it for?
- Any age, women only
- Conditions the study is for
- Breast Cancer
- What is being tested?
- brachytherapy
- Type of treatment
- Surgery or procedure
- How many people
- Not given
- Where
- 232 sitesin 2 countries
- Study dates
- May 1997to Jun 2007
- Phase
- Phase 1/2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Women only
- No healthy volunteers
- Child, Adult, Older adult
DISEASE CHARACTERISTICS: Histologically confirmed nonlobular invasive breast cancer of one of the following histologies: Ductal Papillary Medullary Colloid (mucinous) Tubular Stage I/II (T1-2 N0-1 M0) tumor no greater than 3 cm Prior tylectomy and axillary lymph node dissection required No more than 3 positive axillary lymph nodes and no extracapsular extension At least 6 lymph nodes sampled OR Negative sentinal node Surgical clips in place delineating margins of tylectomy cavity Negative, or close but negative, inked histologic margins of tylectomy or re-excision specimen Negative margins defined as no tumor at least 2 mm away from the inked margins Close but negative margins defined as tumor within 2 mm of inked margin Positive margins defined as invasive or noninvasive tumor at inked resection margins Negative post-tylectomy or post-reexcision mammogram required if disease presented with malignancy-associated microcalcifications No remaining suspicious microcalcifications If catheters are placed at time of reexcision, the crieria may not be feasible but a post brachytherapy mammogram should be obtained as soon as possible No extensive intraductal carcinoma by the Harvard definition, i.e.: More than 25% of tumor is ductal carcinoma in situ (DCIS) and there is DCIS in adjacent breast tissue OR Intraductal carcinoma with microinvasion No proven multicentric carcinoma, i.e.: Tumor in different quadrants of the breast OR Tumor separated by at least 4 cm The following exclude: Skin or chest wall invasion Matted or fixed axillary adenopathy Metastatic internal mammary or supraclavicular nodes Paget's disease of the nipple Previously treated contralateral breast carcinoma or synchronous bilateral breast carcinoma Hormone receptor status: Not specified
PATIENT CHARACTERISTICS: Age: Any age Sex: Female Menopausal status: Not specified Performance status: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: No collagen vascular disease with a c-reactive protein level above normal or with an active skin rash (e.g., systemic lupus erythematosus, scleroderma, or dermatomyositis) No coexisting medical condition that reduces life expectancy to less than 2 years No second malignancy within 5 years except nonmelanomatous skin cancer Not pregnant or nursing Negative pregnancy test
PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy for breast cancer Planned chemotherapy may begin at least 2 weeks after removal of brachytherapy catheters Endocrine therapy: Concurrent tamoxifen permitted Radiotherapy: No prior radiotherapy for breast cancer Surgery: See Disease Characteristics
Trial locations and contacts
232 sites in 2 countries.
232 sites in 2 countries
United States216 sites
Akron General Medical Center
Akron, Ohio, 44302
Akron City Hospital
Akron, Ohio, 44309
Cancer Center of Albany Medical Center
Albany, New York, 12208
Veterans Affairs Medical Center - Albany
Albany, New York, 12208
Saint Joseph Medical Center
Albuquerque, New Mexico, 87102
Providence Cancer Therapy Center
Anchorage, Alaska, 99508
St. John's Medical Center
Anderson, Indiana, 46016
Veterans Affairs Medical Center - Ann Arbor
Ann Arbor, Michigan, 48105
CCOP - Ann Arbor Regional
Ann Arbor, Michigan, 48106
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109-0752
Anne Arundel Oncology Center
Annapolis, Maryland, 21401
Emory University Hospital - Atlanta
Atlanta, Georgia, 30322
CCOP - Atlanta Regional
Atlanta, Georgia, 30342-1701
Marlene & Stewart Greenebaum Cancer Center, University of Maryland
Baltimore, Maryland, 21201
Greater Baltimore Medical Center and Cancer Center
Baltimore, Maryland, 21204
Harbor Hospital Center
Baltimore, Maryland, 21225
Radiation Oncology Affiliates of Maryland, P.A.
Baltimore, Maryland, 21237
Johns Hopkins Oncology Center
Baltimore, Maryland, 21287
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana, 70809
Julie and Ben Rogers Cancer Institute
Beaumont, Texas, 77701
CCOP - Southwestern Vermont Regional Cancer Center
Bennington, Vermont, 05201
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
Veterans Affairs Medical Center - Birmingham
Birmingham, Alabama, 35233
University of Alabama Comprehensive Cancer Center
Birmingham, Alabama, 35294
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114
Joint Center for Radiation Therapy
Boston, Massachusetts, 02215
Medical Center at Bowling Green
Bowling Green, Kentucky, 42102
Bridgeport Hospital
Bridgeport, Connecticut, 06610
State University of New York Health Science Center at Brooklyn
Brooklyn, New York, 11203
New York Methodist Hospital
Brooklyn, New York, 11215-3609
Roswell Park Cancer Institute
Buffalo, New York, 14263-0001
Providence Saint Joseph Medical Center - Burbank
Burbank, California, 91505
Lineberger Comprehensive Cancer Center, UNC
Chapel Hill, North Carolina, 27599-7295
Medical University of South Carolina
Charleston, South Carolina, 29425-0721
Martha Jefferson Hospital
Charlottesville, Virginia, 22901
Northwestern Memorial Hospital
Chicago, Illinois, 60611
University of Chicago Cancer Research Center
Chicago, Illinois, 60637
Christ Hospital
Cincinnati, Ohio, 45219
Lykes Center for Radiation Therapy
Clearwater, Florida, 33757-0210
Ireland Cancer Center
Cleveland, Ohio, 44106-5065
Memorial Hospital Cancer Center
Colorado Springs, Colorado, 80909
Ellis Fischel Cancer Center - Columbia
Columbia, Missouri, 65203
CCOP - Columbus
Columbus, Ohio, 43206
Arthur G. James Cancer Hospital - Ohio State University
Columbus, Ohio, 43210
Mount Diablo Medical Center
Concord, California, 94524-4110
Samaritan Regional Cancer Center
Corvallis, Oregon, 97339
Penn State Geisinger Medical Center
Danville, Pennsylvania, 17822-2001
Mercy Catholic Medical Center, Mercy Fitzgerald Divison
Darby, Pennsylvania, 19023
Veterans Affairs Medical Center - Dayton
Dayton, Ohio, 45428
Halifax Medical Center
Daytona Beach, Florida, 32114
University of Colorado Cancer Center
Denver, Colorado, 80262
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201
Henry Ford Hospital
Detroit, Michigan, 48202
Delaware County Memorial Hospital
Drexel Hill, Pennsylvania, 19026
Beckman Research Institute, City of Hope
Duarte, California, 91010
Wendt Regional Cancer Center of Finley Hospital
Dubuque, Iowa, 52001
Veterans Affairs Medical Center - East Orange
East Orange, New Jersey, 07018-1095
John F. Kennedy Medical Center
Edison, New Jersey, 08818
Elizabeth General Medical Center - West
Elizabeth, New Jersey, 07201
Meritcare Roger Maris Cancer Center
Fargo, North Dakota, 58122
Hurley Medical Center
Flint, Michigan, 48503
Radiation Therapy Associates - Fort Myers
Fort Myers, Florida, 33901
California Cancer Center
Fresno, California, 93720
Saint Agnes Cancer Center
Fresno, California, 93720
University of Florida Health Science Center
Gainesville, Florida, 32610-0296
University of Texas Medical Branch
Galveston, Texas, 77555-1329
Glendale Memorial Hospital and Health Center
Glendale, California, 91204
St. Vincent Hospital
Green Bay, Wisconsin, 54307-3508
Sutter Health Western Division Cancer Research Group
Greenbrae, California, 94904
East Carolina University School of Medicine
Greenville, North Carolina, 27858-4354
CCOP - Greenville
Greenville, South Carolina, 29615
Ingalls Memorial Hospital
Harvey, Illinois, 60426
Penn State Geisinger Cancer Center
Hershey, Pennsylvania, 17033
University of Texas - MD Anderson Cancer Center
Houston, Texas, 77030
Huntsville Hospital System
Huntsville, Alabama, 35801
Cape Cod Hospital
Hyannis, Massachusetts, 02601
Clarion Health Partners Inc.
Indianapolis, Indiana, 46206-1367
Community Hospitals of Indianapolis - Regional Cancer Center
Indianapolis, Indiana, 46219
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242
Jackson-Madison County General Hospital
Jackson, Tennessee, 38301
CCOP - Kalamazoo
Kalamazoo, Michigan, 49007-3731
CCOP - Kansas City
Kansas City, Missouri, 64131
CCOP - Dayton
Kettering, Ohio, 45429
Baptist Regional Cancer Center - Knoxville
Knoxville, Tennessee, 37901
Gundersen Lutheran Medical Foundation
La Crosse, Wisconsin, 54601
Wilford Hall - 59th Medical Wing
Lackland Air Force Base, Texas, 78236-5300
Romagosa Radiation Oncology Center
Lafayette, Louisiana, 70501
CCOP - Southern Nevada Cancer Research Foundation
Las Vegas, Nevada, 89106
Norris Cotton Cancer Center
Lebanon, New Hampshire, 03756
Veterans Affairs Medical Center - Lexington
Lexington, Kentucky, 40511-1093
Albert B. Chandler Medical Center, University of Kentucky
Lexington, Kentucky, 40536-0084
Loma Linda University Medical Center
Loma Linda, California, 92354
Veterans Affairs Medical Center - Long Beach
Long Beach, California, 90822
Kaiser Permanente Medical Center - Los Angeles
Los Angeles, California, 90027
USC/Norris Comprehensive Cancer Center
Los Angeles, California, 90033-0800
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, 90095-1781
James Graham Brown Cancer Center
Louisville, Kentucky, 40202
Louisville Radiation Oncology
Louisville, Kentucky, 40215
Virginia Baptist Hospital
Lynchburg, Virginia, 24503
Veterans Affairs Medical Center - Madison
Madison, Wisconsin, 53705
Southern Wisconsin Radiotherapy Center
Madison, Wisconsin, 53713
University of Wisconsin Comprehensive Cancer Center
Madison, Wisconsin, 53792
Merle M. Mahr Cancer Center
Madisonville, Kentucky, 42431
Elliot Regional Cancer Center
Manchester, New Hampshire, 03103
CCOP - North Shore University Hospital
Manhasset, New York, 11030
Marquette General Hospital
Marquette, Michigan, 49855
Marshfield Clinic
Marshfield, Wisconsin, 54449
Veterans Affairs Outpatient Clinic - Martinez
Martinez, California, 94553
Loyola University Medical Center
Maywood, Illinois, 60153
Health First Holmes Regional Medical Center
Melbourne, Florida, 32901
CCOP - Baptist Cancer Institute
Memphis, Tennessee, 38117
University of Tennessee, Memphis Cancer Center
Memphis, Tennessee, 38163
Community Memorial Hospital
Menomonee Falls, Wisconsin, 53051
East Jefferson General Hospital
Metairie, Louisiana, 70011
Sylvester Cancer Center, University of Miami
Miami, Florida, 33136
Baptist Hospital of Miami
Miami, Florida, 33176-2197
CCOP - Mount Sinai Medical Center
Miami Beach, Florida, 33140
South Jersey Hospital - Millville
Millville, New Jersey, 08332
St. Joseph's Hospital
Milwaukee, Wisconsin, 53210
Columbia Hospital
Milwaukee, Wisconsin, 53211
St. Luke's Medical Center
Milwaukee, Wisconsin, 53215
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
Veterans Affairs Medical Center - Milwaukee (Zablocki)
Milwaukee, Wisconsin, 53295
UNI-MED Medical Center
Minot, North Dakota, 58701
Urology Associates - Mobile AL
Mobile, Alabama, 36640
MBCCOP - University of South Alabama
Mobile, Alabama, 36688
Alabama Oncology, LLC
Montgomery, Alabama, 36106-2801
Fox Chase Cancer Center at Virtua-Memorial Hospital Burlington County
Mount Holly, New Jersey, 08060
Ball Memorial Hospital
Muncie, Indiana, 47303-3499
Vanderbilt Cancer Center
Nashville, Tennessee, 37232-6838
MBCCOP - LSU Medical Center
New Orleans, Louisiana, 70112
CCOP - Ochsner
New Orleans, Louisiana, 70121
Kaplan Cancer Center
New York, New York, 10016
Memorial Sloan-Kettering Cancer Center
New York, New York, 10021
Whittingham Cancer Center
Norwalk, Connecticut, 06856
CCOP - Bay Area Tumor Institute
Oakland, California, 94609-3305
Methodist Cancer Center - Omaha
Omaha, Nebraska, 68114
CCOP - Missouri Valley Cancer Consortium
Omaha, Nebraska, 68131
Florida Radiation Oncology Group
Orange Park, Florida, 32073
MD Anderson Cancer Center Orlando
Orlando, Florida, 32806
Western Baptist Hospital
Paducah, Kentucky, 42001
Gulf Coast Cancer Treatment Center
Panama City, Florida, 32405-4587
Lutheran General Cancer Care Center
Park Ridge, Illinois, 60068
Bayshore Medical Center
Pasadena, Texas, 77504
West Florida Cancer Institute - Pensacola
Pensacola, Florida, 32514
Methodist Medical Center of Illinois
Peoria, Illinois, 61636
Allegheny University Hospitals- Hahnemann
Philadelphia, Pennsylvania, 19102-1192
University of Pennsylvania Cancer Center
Philadelphia, Pennsylvania, 19104
Veterans Affairs Medical Center - Philadelphia
Philadelphia, Pennsylvania, 19104
Kimmel Cancer Center of Thomas Jefferson University - Philadelphia
Philadelphia, Pennsylvania, 19107
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111
Albert Einstein Cancer Center
Philadelphia, Pennsylvania, 19141
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, 15213
Western Pennsylvania Hospital
Pittsburgh, Pennsylvania, 15224
Champlain Valley Physicians Hospital Medical Center
Plattsburgh, New York, 12901
Cancer Care Center
Pomona, California, 91767
Maine Medical Center
Portland, Maine, 04102
CCOP - Columbia River Program
Portland, Oregon, 97213
Naval Medical Center, Portsmouth
Portsmouth, Virginia, 23708-2197
Vassar Brothers Hospital
Poughkeepsie, New York, 12601
Southeastern Wisconsin Regional Cancer Center
Racine, Wisconsin, 53405
Reading Hospital and Medical Center
Reading, Pennsylvania, 19612-6052
Mercy Medical Center - Redding
Redding, California, 96099-6009
Massey Cancer Center
Richmond, Virginia, 23298-0037
Mayo Clinic Cancer Center
Rochester, Minnesota, 55905
Genesee Hospital - Rochester
Rochester, New York, 14607
University of Rochester Cancer Center
Rochester, New York, 14642
InterCommunity Cancer Center at Rome
Rome, Georgia, 30161
Green Mountain Oncology Group
Rutland, Vermont, 05701
Radiation Oncology Center - Sacramento
Sacramento, California, 95816
St. Mary's Medical Center
Saginaw, Michigan, 48601
CCOP - Metro-Minnesota
Saint Louis Park, Minnesota, 55416
LDS Hospital
Salt Lake City, Utah, 84143
UCSF Cancer Center and Cancer Research Institute
San Francisco, California, 94115-0128
Santa Cruz Radiation Oncology Medical Group, Inc.
Santa Cruz, California, 95065
CCOP - Santa Rosa Memorial Hospital
Santa Rosa, California, 95403
Mercy Hospital Cancer Center - Scranton
Scranton, Pennsylvania, 18501
Swedish Hospital Tumor Institute
Seattle, Washington, 98104
Virginia Mason Medical Center
Seattle, Washington, 98111
Grand View Hospital
Sellersville, Pennsylvania, 18960
Memorial Hospital of South Bend
South Bend, Indiana, 46601
St. Joseph's Radiation Oncology Center
South Bend, Indiana, 46617
CCOP - Upstate Carolina
Spartanburg, South Carolina, 29303
Deaconess Medical Center
Spokane, Washington, 99210-0248
CCOP - Central Illinois
Springfield, Illinois, 62526
Cancer Research for the Ozarks
Springfield, Missouri, 65807
CCOP - Ozarks Regional
Springfield, Missouri, 65807
Veterans Affairs Medical Center - Saint Louis
St Louis, Missouri, 63106
St. Louis University Health Sciences Center
St Louis, Missouri, 63110-0250
Mallinckrodt Institute of Radiology
St Louis, Missouri, 63110
Dixie Regional Medical Center
St. George, Utah, 84770
Bayfront Medical Center
St. Petersburg, Florida, 33701
Stanford University
Stanford, California, 94305
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612
Albert Einstein Comprehensive Cancer Center
The Bronx, New York, 10461
CCOP - Toledo Community Hospital Oncology Program
Toledo, Ohio, 43623-3456
Community Medical Center
Toms River, New Jersey, 08755
David Grant Medical Center
Travis Air Force Base, California, 94535
St. Francis Medical Center
Trenton, New Jersey, 08629
Arizona Cancer Center
Tucson, Arizona, 85724
St. John Medical Center
Tulsa, Oklahoma, 74104
Radiation Oncology Associates of West Alabama
Tuscallosa, Alabama, 35401
CCOP - Carle Cancer Center
Urbana, Illinois, 61801
South Georgia Medical Center
Valdosta, Georgia, 31603
New York Medical College
Valhalla, New York, 10595
Radiation Oncology Center - Walnut Creek
Walnut Creek, California, 94598
Walter Reed Army Medical Center
Washington D.C., District of Columbia, 20307-5000
Schiffler Oncology Center
Wheeling, West Virginia, 26003
Veterans Affairs Medical Center - White River Junction
White River Junction, Vermont, 05009
Wilkes Barre General Hospital
Wilkes-Barre, Pennsylvania, 18764
CCOP - Christiana Care Health Services
Wilmington, Delaware, 19899
CCOP - Southeast Cancer Control Consortium
Winston-Salem, North Carolina, 27104-4241
Comprehensive Cancer Center of Wake Forest University Baptist Medical Center
Winston-Salem, North Carolina, 27157-1082
CCOP - MainLine Health
Wynnewood, Pennsylvania, 19096
Yakima Valley Memorial Hospital
Yakima, Washington, 98902
York Hospital
York, Pennsylvania, 17315
Canada16 sites
Tom Baker Cancer Center - Calgary
Calgary, Alberta, T2N 4N2
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2
Northeastern Ontario Regional Cancer Centre, Sudbury
Greater Sudbury, Ontario, P3E 5J1
Nova Scotia Cancer Centre
Halifax, Nova Scotia, B3H 1V7
Cancer Care Ontario-Hamilton Regional Cancer Centre
Hamilton, Ontario, L8V 5C2
Kingston Regional Cancer Centre
Kingston, Ontario, K7L 5P9
Cancer Care Ontario-London Regional Cancer Centre
London, Ontario, N6A 4L6
Doctor Leon Richard Oncology Centre
Moncton, New Brunswick, E1C 8X3
McGill University Department of Oncology
Montreal, Quebec, H2W 1S6
Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, H2W-W1T8
Ottawa Regional Cancer Centre - Civic Campus
Ottawa, Ontario, K1Y 4K7
Saint John Regional Hospital
Saint John, New Brunswick, E2L 4L2
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, S7N 4H4
Northwestern Ontario Regional Cancer Centre, Thunder Bay
Thunder Bay, Ontario, P7A 7T1
Princess Margaret Hospital
Toronto, Ontario, M5G 2M9
British Columbia Cancer Agency - Vancouver Island Cancer Centre
Victoria, British Columbia, V8R 1J8
About this study
Official title: A PHASE I/II TRIAL TO EVALUATE BRACHYTHERAPY AS THE SOLE METHOD OF RADIATION THERAPY FOR STAGE I AND II BREAST CARCINOMA
RATIONALE: Radiation therapy may kill any tumor cells remaining after surgery.
PURPOSE: Phase I/II trial to study the effectiveness of brachytherapy in treating women who have stage I or stage II breast cancer.
Read the detailed description
OBJECTIVES: I. Evaluate the technical feasibility and reproducibility, cosmetic results, complication rates, and local cancer control rate experience with brachytherapy used as the sole method of radiotherapy in women with stage I/II breast cancer treated with tylectomy who have histologically assessed negative surgical margins, less than 4 positive axillary nodes, and no extracapsular nodal extension or extensive intraductal component. II. Reduce the total treatment time of breast irradiation from 6 weeks to 4-5 days in these patients.
OUTLINE: Treatment begins no sooner than 4 days and within 6 weeks after definitive surgery. All patients receive brachytherapy to the target volume (as defined by the excision cavity demarcated by post-tylectomy surgical clips plus 2 cm margin) using iridium-192 implants for dose distribution to five planes. Patients may be treated with either high-dose-rate or low-dose-rate brachytherapy at the institution's discretion. Patients are followed at 2 and 6 weeks after treatment, then at 3, 6, 9 and 12 months, then every 4 months for 1 year, every 6 months for 3 years, and then annually thereafter.
PROJECTED ACCRUAL: A maximum of 46 patients will be accrued in each group (high-dose rate vs low-dose rate) over 2 years.
- Conditions
- Breast Cancer
- Being tested
- brachytherapy
- Keywords
- stage I breast cancer, stage II breast cancer, medullary ductal breast carcinoma with lymphocytic infiltrate, mucinous ductal breast carcinoma, invasive ductal breast carcinoma, papillary ductal breast carcinoma, tubular ductal breast carcinoma
- Medical subject headings
- Breast Neoplasms, Carcinoma, Ductal, Breast
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
brachytherapyRadiation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Sep 2004 (estimated)
- Study startMay 1997
- Primary completionJun 2007
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
Sponsor and investigators
- Lead sponsor
- Radiation Therapy Oncology Group
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Robert R. Kuske, MD, Study chair, Ochsner Cancer Institute at Ochsner Clinic Foundation
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00002873
- Sponsor's protocol ID
- RTOG-9517
- Other IDs
- CDR0000065157
- Status last verified
- Feb 2008
- First submitted
- 1 Nov 1999
- Last updated
- 19 Jul 2013
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Arthur DW, Winter K, Kuske RR, Bolton J, Rabinovitch R, White J, Hanson WF, Wilenzick RM, McCormick B. A Phase II trial of brachytherapy alone after lumpectomy for select breast cancer: tumor control and survival outcomes of RTOG 95-17. Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):467-73. doi: 10.1016/j.ijrobp.2007.12.056. Epub 2008 Mar 4.
PubMed 18294778Ibbott GS, Hanson WF, O'Meara E, Kuske RR, Arthur D, Rabinovitch R, White J, Wilenzick RM, Harris I, Tailor RC. Dose specification and quality assurance of radiation therapy oncology group protocol 95-17; a cooperative group study of iridium-192 breast implants as sole therapy. Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1572-8. doi: 10.1016/j.ijrobp.2007.08.011.
PubMed 18035213Rabinovitch R, Winter K, Kuske R, Bolton J, Arthur D, Scroggins T, Vicini F, McCormick B, White J. RTOG 95-17, a Phase II trial to evaluate brachytherapy as the sole method of radiation therapy for Stage I and II breast carcinoma--year-5 toxicity and cosmesis. Brachytherapy. 2014 Jan-Feb;13(1):17-22. doi: 10.1016/j.brachy.2013.08.002. Epub 2013 Sep 14.
PubMed 24041956Kuske RR, Winter K, Arthur DW, et al.: A phase II trial of brachytherapy alone following lumpectomy for stage I or II breast cancer: initial outcomes of RTOG 9517. [Abstract] J Clin Oncol 22 (Suppl 14): A-565, 18s, 2004.
Kuske RR, Winter K, Arthur D, et al.: A phase I/II trial of brachytherapy alone following lumpectomy for select breast cancer: toxicity analysis of Radiation Therapy Oncology Group 95-17. [Abstract] Int J Radiat Oncol Biol Phys 54(2 suppl 1): A-151, 87, 2002.
Study at a glance
From the registry record, last updated by the sponsor on 19 Jul 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A PHASE I/II TRIAL TO EVALUATE BRACHYTHERAPY AS THE SOLE METHOD OF RADIATION THERAPY FOR STAGE I AND II BREAST CARCINOMA
- ClinicalTrials.gov ID
- NCT00002873
- Acronym / sponsor ID
- RTOG-9517
- Conditions
- Breast Cancer
- Keywords
- stage I breast cancer, stage II breast cancer, medullary ductal breast carcinoma with lymphocytic infiltrate, mucinous ductal breast carcinoma, invasive ductal breast carcinoma, papillary ductal breast carcinoma, tubular ductal breast carcinoma
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Completed
- Lead sponsor
- Radiation Therapy Oncology GroupResearch network
- Collaborators
- National Cancer Institute (NCI)
- Study start
- May 1997
- Primary completion
- Jun 2007 (actual)
- First posted
- 2 Sep 2004 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Radiation therapy may kill any tumor cells remaining after surgery.
PURPOSE: Phase I/II trial to study the effectiveness of brachytherapy in treating women who have stage I or stage II breast cancer.
Detailed description
OBJECTIVES: I. Evaluate the technical feasibility and reproducibility, cosmetic results, complication rates, and local cancer control rate experience with brachytherapy used as the sole method of radiotherapy in women with stage I/II breast cancer treated with tylectomy who have histologically assessed negative surgical margins, less than 4 positive axillary nodes, and no extracapsular nodal extension or extensive intraductal component. II. Reduce the total treatment time of breast irradiation from 6 weeks to 4-5 days in these patients.
OUTLINE: Treatment begins no sooner than 4 days and within 6 weeks after definitive surgery. All patients receive brachytherapy to the target volume (as defined by the excision cavity demarcated by post-tylectomy surgical clips plus 2 cm margin) using iridium-192 implants for dose distribution to five planes. Patients may be treated with either high-dose-rate or low-dose-rate brachytherapy at the institution's discretion. Patients are followed at 2 and 6 weeks after treatment, then at 3, 6, 9 and 12 months, then every 4 months for 1 year, every 6 months for 3 years, and then annually thereafter.
PROJECTED ACCRUAL: A maximum of 46 patients will be accrued in each group (high-dose rate vs low-dose rate) over 2 years.
Study design
- Primary purpose
- Treatment
Who may qualify
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| brachytherapy | Radiation | – |
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Jul 2013.
- Results publication: PubMed 18294778Arthur DW, Winter K, Kuske RR, Bolton J, Rabinovitch R, White J, Hanson WF, Wilenzick RM, McCormick B. A Phase II trial of brachytherapy alone after lumpectomy for select breast cancer: tumor control and survival outcomes of RTOG 95-17. Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):467-73. doi: 10.1016/j.ijrobp.2007.12.056. Epub 2008 Mar 4.
- Results publication: PubMed 18035213Ibbott GS, Hanson WF, O'Meara E, Kuske RR, Arthur D, Rabinovitch R, White J, Wilenzick RM, Harris I, Tailor RC. Dose specification and quality assurance of radiation therapy oncology group protocol 95-17; a cooperative group study of iridium-192 breast implants as sole therapy. Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1572-8. doi: 10.1016/j.ijrobp.2007.08.011.
- Results publication: PubMed 24041956Rabinovitch R, Winter K, Kuske R, Bolton J, Arthur D, Scroggins T, Vicini F, McCormick B, White J. RTOG 95-17, a Phase II trial to evaluate brachytherapy as the sole method of radiation therapy for Stage I and II breast carcinoma--year-5 toxicity and cosmesis. Brachytherapy. 2014 Jan-Feb;13(1):17-22. doi: 10.1016/j.brachy.2013.08.002. Epub 2013 Sep 14.
- Results publicationKuske RR, Winter K, Arthur DW, et al.: A phase II trial of brachytherapy alone following lumpectomy for stage I or II breast cancer: initial outcomes of RTOG 9517. [Abstract] J Clin Oncol 22 (Suppl 14): A-565, 18s, 2004.
- Results publicationKuske RR, Winter K, Arthur D, et al.: A phase I/II trial of brachytherapy alone following lumpectomy for select breast cancer: toxicity analysis of Radiation Therapy Oncology Group 95-17. [Abstract] Int J Radiat Oncol Biol Phys 54(2 suppl 1): A-151, 87, 2002.
Related trials for Breast Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Robert R. Kuske, MD study chair
Ochsner Cancer Institute at Ochsner Clinic Foundation
232 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing brachytherapy in people with Breast Cancer, run by Radiation Therapy Oncology Group at 232 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Jul 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 232 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00002873, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Jul 2013.